Hypoactive sexual desire disorder(HSDD)is a widely known type of female sexual dysfunction that could also cause emotional distress and relationship problems.Flibanserin,a benzimidazole,was being studied as a treatmen...Hypoactive sexual desire disorder(HSDD)is a widely known type of female sexual dysfunction that could also cause emotional distress and relationship problems.Flibanserin,a benzimidazole,was being studied as a treatment for premenopausal women with hypoactive sexual desire disorder because there was no accurate drug therapy available at the time(HSDD).The US Food and Drug Administration(FDA)approved Flibanserin in 2015 for the treatment of generalised acquired HSDD in premenopausal women.It has a high affinity for postsynaptic 5-HT-1A receptors(agonist)and 5-HT-2A receptors(antagonist),and it tends to work by increasing dopamine and noradrenaline levels in the brain while decreasing serotonin levels.This review was to assess Flibanserin efficacy and safety and it is found the drug Flibanserin benefits did not outweigh the risks in premenopausal and postmenopausal women.展开更多
女性性功能障碍(female sexual dysfunctions,FSD)虽然不是威胁生命的疾病,但可能会伴随女性一生,产生心理困扰并导致整体生活质量明显降低。FSD患病率为25.8%~91.0%,差异很大。第四届国际性医学专家学术会(the 4th International Consu...女性性功能障碍(female sexual dysfunctions,FSD)虽然不是威胁生命的疾病,但可能会伴随女性一生,产生心理困扰并导致整体生活质量明显降低。FSD患病率为25.8%~91.0%,差异很大。第四届国际性医学专家学术会(the 4th International Consultation on Sexual Medicine,ICSM)指出女性性问题患病率在40%~50%之间[1]。展开更多
文摘Hypoactive sexual desire disorder(HSDD)is a widely known type of female sexual dysfunction that could also cause emotional distress and relationship problems.Flibanserin,a benzimidazole,was being studied as a treatment for premenopausal women with hypoactive sexual desire disorder because there was no accurate drug therapy available at the time(HSDD).The US Food and Drug Administration(FDA)approved Flibanserin in 2015 for the treatment of generalised acquired HSDD in premenopausal women.It has a high affinity for postsynaptic 5-HT-1A receptors(agonist)and 5-HT-2A receptors(antagonist),and it tends to work by increasing dopamine and noradrenaline levels in the brain while decreasing serotonin levels.This review was to assess Flibanserin efficacy and safety and it is found the drug Flibanserin benefits did not outweigh the risks in premenopausal and postmenopausal women.
文摘女性性功能障碍(female sexual dysfunctions,FSD)虽然不是威胁生命的疾病,但可能会伴随女性一生,产生心理困扰并导致整体生活质量明显降低。FSD患病率为25.8%~91.0%,差异很大。第四届国际性医学专家学术会(the 4th International Consultation on Sexual Medicine,ICSM)指出女性性问题患病率在40%~50%之间[1]。
